CLSA PREMIUM (06877) announced audited results for the year ended December 31, 2023. Total revenue from continuing operations was approximately HK$200 million, up 410.37% year on year; annual profit from continuing operations of HK$12.83 million, which turned a year-on-year loss into profit; annual profit of HK$9.842 million, while a loss of HK$31.05 million was recorded in the same period in 2022; and profit of HK$0.48 per share.
According to reports, the increase in net profit was mainly due to significant growth in the health care business in 2023, and the revenue from sales of health products exceeded 3 times that of 2022.